Clinical characteristics of patients newly diagnosed with COPD by the fixed ratio and lower limit of normal criteria: a cross-sectional analysis of the TargetCOPD trial

Martin R Miller¹
Shamil Haroon¹
Rachel E Jordan¹
Alice J Sitch¹
Andrew P Dickens¹
Alexandra Enocson¹
David A Fitzmaurice²
Peyman Adab¹
¹Institute of Applied Health Research, College of Medical and Dental Sciences, University of Birmingham, Edgbaston, Birmingham, UK; ²Warwick Clinical Trials Unit, Warwick Medical School, University of Warwick, Coventry, UK

Background: Consensus on the definition of airflow obstruction to diagnose COPD remains unresolved.

Methods: We undertook systematic case finding for COPD in primary care using the fixed ratio (FR) criterion (forced expiratory volume in 1 s/forced vital capacity [FEV₁/FVC] <0.7) for defining airflow obstruction and also using the lower limit of normal (LLN). We then compared the clinical characteristics of those identified by the 2 criteria.

Results: A total of 3,721 individuals reporting respiratory symptoms were invited for spirometry. A total of 2,607 attended (mean age 60.4 years, 52.8% male, 29.8% current smokers) and 32.6% had airflow obstruction by FR (“FR+”) and 20.2% by LLN (“LLN+”). Compared with the LLN+/FR+ group, the LLN−/FR+ group (12.4%) was significantly older, had higher FEV₁ and FEV₁/FVC, lower COPD assessment test scores, and less cough, sputum, and wheeze, but was significantly more likely to report a diagnosis of heart disease (14.2% versus 6.9%, p<0.001). Compared with the LLN+/FR+ group, the LLN−/FR− group was younger, had a higher body mass index, fewer pack-years, a lower prevalence of respiratory symptoms except for dyspnea, and lower FVC and higher FEV₁. The probability of known heart disease was significantly lower in the LLN+/FR+ group compared with those with preserved lung function (LLN−/FR−) (adjusted odds ratio 0.62, 95% CI: 0.43–0.90) but this was not seen in the LLN−/FR+ group (adjusted odds ratio 0.90, 95% CI: 0.63–1.29).

Conclusion: In symptomatic individuals, defining airflow obstruction by FR instead of LLN identifies a significant number of individuals who have less respiratory and more cardiac clinical characteristics.

Keywords: lower limit of normal, diagnostic criteria, primary care

Introduction
COPD is the third leading cause of premature mortality and the fifth leading cause of disability adjusted life years globally.¹ Huge efforts have been made to improve the diagnosis of COPD in primary care. However, the definition of COPD remains an unresolved issue with controversy remaining about the criteria for defining airflow obstruction. The Global Initiative for Obstructive Lung Disease (GOLD) and the National Institute for Health and Care Excellence (NICE) in the UK recommend the use of a fixed ratio (FR) of forced expiratory volume in 1 s (FEV₁) to forced vital
capacity (FVC) of <0.7 as the diagnostic threshold for airflow obstruction.\(^2\) However, this criterion does not take into consideration that FEV\(_1\)/FVC declines with age and differs between the sexes and by ethnicity.\(^3\)

A number of epidemiological analyses suggest that using the FR criterion misclassifies a significant proportion of healthy older men as having airflow obstruction and underdiagnoses younger females.\(^4\) There is also particular concern that using this criterion misclassifies patients with breathlessness due to cardiovascular disease\(^5\) who then may miss out on necessary treatment, while receiving inappropriate medication and potentially adverse outcomes.\(^6,7\) The European Respiratory Society (ERS) and American Thoracic Society (ATS) recommend using a more statistics-based definition of airflow obstruction derived from population-based reference values.\(^8\)

This defines individuals with an FEV\(_1\)/FVC below the lower limit of normal (LLN; below the fifth percentile adjusted for age, sex, height, and ethnic group), as having airflow obstruction.\(^9\) There is increasing evidence that this approach correlates better with clinical outcomes than the FR.\(^10\)

With increasing emphasis on actively case finding undiagnosed COPD,\(^2\) there is potential for large numbers of new cases to be diagnosed.\(^11\) In this context, it is important that misdiagnosis is avoided and those more likely to benefit are identified. A large randomized controlled trial was conducted in the West Midlands, UK, evaluating the effectiveness and cost-effectiveness of COPD case finding in primary care.\(^12,13\) This trial offered spirometry to subjects with respiratory symptoms aged >40 years. The objective of the present study was to compare the clinical characteristics of symptomatic patients in primary care with case-found COPD diagnosed when using the FR criterion with those identified when using the LLN.

**Methods**

**Study design**

This is a post hoc cross-sectional analysis of data from TargetCOPD, which was a cluster-randomized controlled trial based in primary care that compared 2 approaches to COPD case finding against usual care. Full details of the trial have been previously described.\(^12\) In the case-finding arm, patients aged 40–79 years with no prior diagnosis of COPD were eligible. Participants were provided with respiratory questionnaires that ascertained information on demographic characteristics, symptoms, smoking history, and self-reported comorbidities. Responders reporting respiratory symptoms (either chronic cough/phlegm for ≥3 months for at least 2 years, or wheeze in the last 12 months, or Medical Research Council [MRC] grade 2 dyspnea or worse) were invited for a spirometry assessment. The current analysis used data from subjects recruited in practices randomized to the case-finding arm of the trial who attended a spirometry assessment.

**Setting**

The case-finding arm of TargetCOPD included 27 general practices from the West Midlands, UK, with participation from August 2012 to June 2014.

**Participants**

All subjects included in this analysis had participated in the case-finding arm of TargetCOPD, had reported at least 1 respiratory symptom (as detailed previously), had provided written informed consent, and had attended a spirometry assessment. Subjects were identified through electronic searches of general practice registers. Initially, only ever smokers were eligible, although due to difficulties with accurate identification from primary care health records, never smokers were also included. General practitioners could exclude patients at their discretion if, for example, they had dementia, a recent bereavement, or terminal diagnosis.

**Spirometry assessment**

Spirometry was performed by research assistants who had been trained using a short modified program modeled on the Association of Respiratory Technologists and Physiologists spirometry course at the lung function laboratory at Queen Elizabeth Hospital Birmingham. The research assistants also received additional training every 6 months during the course of the study. Post-bronchodilator spirometry was performed according to ATS and ERS guidelines using EasyOne ultrasonic flow head spirometers (ndd Medical Technologies, Zurich) with bespoke software (developed by MRM). Four 100 µg doses of salbutamol were administered via a Volumatic spacer 20 min prior to performing spirometry. Every spirometry trace was over-read and quality assured by a lung function specialist (MRM) and spirometers underwent daily calibration checks. Patients’ height was measured to the nearest centimeter using a portable stadiometer (or estimated from arm-span where necessary).

**Diagnosis of COPD**

COPD was defined as having airflow obstruction according to 2 separate criteria, among those with respiratory symptoms (as described previously):

1. Post-bronchodilator FEV\(_1\)/FVC<LLN, defined as a z-score for FEV\(_1\)/FVC below the fifth percentile from the GLI 2012 lung function reference equations (“LLN criterion”).\(^10\)

2. Post-bronchodilator FEV\(_1\)/FVC<0.7 (“FR criterion”).
Data from self-reported questionnaires were available on sociodemographic characteristics (age, sex, ethnic group, and socioeconomic status), smoking status (including pack-years), self-reported comorbidities (hypertension, heart disease, heart failure, diabetes, stroke, lung cancer, tuberculosis, and depression), respiratory symptoms (cough, phlegm, wheeze, dyspnea, and rhinorrhea), COPD assessment test (CAT) scores, and overall quality of life (EQ-5D).

Statistical methods
The sociodemographic and clinical characteristics of subjects were summarized separately according to the following 4 diagnostic groupings:
1. Normal spirometry according to both LLN and FR criteria (LLN−/FR−).
2. Airflow obstruction according to both criteria (LLN+/FR+).
3. Airflow obstruction according to the FR but not LLN (LLN−/FR+).
4. Airflow obstruction according to LLN but not the FR (LLN+/FR−).

Continuous variables were summarized as means and SDs and categorical variables as percentages. The FEV1, FVC, and FEV1/FVC ratio were summarized as z-scores using GLI 2012 equations. Clinical characteristics were compared across groups using Kruskal–Wallis H-tests for continuous variables (as they had skewed distributions), and chi-squared tests for categorical variables. The main comparisons were bivariate analyses between the LLN+/FR+ and LLN−/FR+ groups, and between the LLN+/FR+ and LLN−/FR− groups, comparing the prevalence of each characteristic. The p-value thresholds for statistical significance were adjusted for multiple testing using the Bonferroni correction.

Since previous literature has suggested that use of the FR tends to include more patients with cardiovascular disease than the LLN criteria, we tested this hypothesis in our data using a logistic regression model with self-reported cardiovascular disease (composite outcome of self-reported heart disease and/or heart failure) as the outcome, and LLN/FR status as an independent variable with models derived adjusting for age, sex, smoking status, self-reported diabetes mellitus, and hypertension.

Ethical approval
Research governance and ethics approval for TargetCOPD was provided by the Solihull Research Ethics Committee (Ref: 11/WM/0403).

Results
The case-finding arm of TargetCOPD had 32,811 eligible participants. Questionnaires were given to 22,116 and 7,778 responded, of whom, 4,355 (56%) reported respiratory symptoms. From those with symptoms, 3,721 were invited for a spirometry assessment and 2,607 (70%) attended and were included in the current analysis (Figure 1).

The mean age of the included 2,607 participants was 60.4 years, 52.8% were male, and 29.8% were current smokers. The demographic characteristics, smoking status, BMI, and spirometry results are summarized in Table 1, stratified by diagnostic criteria for airflow obstruction. There were 851 (32.6%) individuals with airflow obstruction according to the FR, of whom, 527 (20.2%) met the LLN criterion (LLN+/FR+). A total of 324 (12.4%) had airflow obstruction only by the FR but not by the LLN (LLN−/FR+), and 1,753 (67.2%) did not meet the criteria for airflow obstruction by either criteria (Figure 1). Not included in Table 1 are 3 individuals with airflow obstruction by the LLN but not identified by the FR criterion. They were all younger females (mean age 46.1 years), with a mean pack-year history of 2.9, BMI of 31.3, and FEV1/FVC z-score of −1.73.

Compared with the LLN+/FR+ group, patients in the LLN−/FR+ group were older and had better lung function (higher FEV1, and FEV1/FVC z-scores). A higher proportion was male, although this difference was not statistically significant. However, smoking pack-years was similar between the LLN+/FR+ and LLN−/FR+ groups, both of which were significantly higher than for subjects with preserved lung function (LLN−/FR−). Compared with the LLN+/FR+ group,
subjects in the LLN-/FR− group were younger, and had a higher BMI, fewer pack-years, and worse zFVC but higher zFEV₁ and zFEV₁/zFVC.

Table 2 summarizes the symptoms, self-reported comorbidities, and quality of life for participants, stratified by diagnostic group. Symptoms of cough, sputum, and wheeze were all more prevalent in the LLN+/FR+ group compared with the LLN-/FR+ group. CAT scores were 2 points higher (equivalent to the minimum clinically significant difference in the LLN+/FR+ than the LLN-/FR+ group, although there was a substantial amount of missing data (12.8%) for this variable. However, there were no significant differences in overall quality of life (as measured by EQ-5D). In contrast to the LLN+/FR+ group, the overall symptom burden in the LLN-/FR+ group was similar to the unobstructed group (LLN-/FR−), except for a slightly higher prevalence of wheeze. The 3 patients with airflow obstruction by the LLN but not by the FR criterion were significantly more symptomatic than the other groups with a mean CAT score of 17.

The prevalence of heart disease was significantly higher in the LLN-/FR+ group compared with the LLN+/FR+ group (14.2% versus 6.9%, p<0.001) but the LLN+/FR+ group also had a significantly lower prevalence of depression (Table 2; Figure 2). The prevalence of asthma was significantly higher in the LLN+/FR+ group compared with the LLN-/FR− group (30.9% versus 18.4%, p<0.001). While this was also observed when comparing the LLN+/FR+ with the LLN-/FR+ group, this difference did not reach statistical significance. After adjusting for age and sex, the LLN+/FR+ group had a significantly lower probability of having heart disease compared with the LLN-/FR− group (odds ratio 0.57, 95% CI: 0.40–0.81) but no significant difference was found for the LLN-/FR+ group (Table 3). The same associations

| Participant characteristics | LLN+/FR+ | p-value | LLN-/FR− | LLN-/FR+ |
|-----------------------------|----------|---------|----------|----------|
| Subjects                    | N (%)    | p-value | N (%)    | p-value |
| Male                        | 292 (53.4) | 0.056   | 196 (60.5) | 0.145   |
| Age (years)                 | Mean (SD) | 0.0001* | Mean (SD) | 0.0001* |
| 40–49                       | 81 (15.4)  | 3 (0.9)  | 41 (12.7) | 523 (29.8) |
| 60–69                       | 185 (35.1) | 130 (40.1) | 484 (27.6) |
| 70–79                       | 122 (23.1) | 150 (46.3) | 310 (17.7) |
| Ethnicity                   | White    | 472 (89.7) | 300 (92.6) | 1,477 (84.4) |
| 10 (1.9)                    | 6 (1.9)  | 527 (23.1) | 384 (27.6) |
| 126 (4.9)                   | 7 (2.2)  | 41 (12.7) | 523 (29.8) |
| Mixed                       | 5 (1.0)  | 0 (0.0)  | 25 (1.4) |
| Other                       | 14 (2.7)  | 11 (3.4) | 49 (2.8) |
| BMI (kg/m²)                 | Mean (SD) | 0.0001* | Mean (SD) | 0.0001* |
| < 18.5                      | 6 (1.1)  | 2 (0.6)  | 5 (0.3) |
| 18.5–24.9                   | 127 (24.2) | 63 (19.5) | 280 (16.1) |
| 25.0–29.9                   | 193 (36.8) | 121 (37.5) | 649 (37.3) |
| ≥ 30                        | 201 (38.4) | 138 (42.7) | 819 (47.0) |
| Lung function               | FEV₁ L (SD) | 2.19 (0.68) | 2.43 (0.64) | 2.81 (0.74) |
| zFEV₁ (SD)                  | −1.59 (0.99) | 0.0001* | −0.69 (0.89) | 0.0001* |
| zFVC L (SD)                 | 3.73 (1.03)  | 3.60 (0.94) | 3.62 (0.95) |
| zFVC (SD)                   | 0.01 (1.11)  | 0.07 (1.04) | 0.58 |
| FEV₁/FVC (SD)               | 0.59 (0.08)  | 0.67 (0.02) | 0.78 (0.05) |
| zFEV₁/FVC                   | −2.48 (0.68) | 0.0001* | −1.28 (0.26) | 0.0001* |
| Pack years                  | Mean (SD) | 25.2 (21.4) | 25.3 (27.6) | 16.9 (20.1) |
| Smearing status             | Never     | 71 (13.5)  | 52 (16.6) | 422 (24.4) |
| Former                      | 212 (40.5) | 207 (64.9) | 843 (48.6) |
| Current                     | 241 (46.0) | 59 (18.5)  | 468 (27.0) |

Notes: z prefix denotes the z-score for the lung function index. *Unless otherwise specified. The results for LLN-/FR+ were compared with LLN+/FR+ ($) and results for LLN+/FR− were compared with LLN−/FR− (‡) using Pearson Chi-square test for sex differences and Kruskal–Wallis tests for the other indices. *p-values ≤0.001 are significant in accordance with Bonferroni correction for multiple comparisons.

Abbreviations: FEV₁, forced expiratory volume in 1 s; FR, fixed ratio; FVC, forced vital capacity; LLN, lower limit of normal; BMI, body mass index.

Table 1 Demographic characteristics and spirometry results stratified by diagnostic criteria

The prevalence of heart disease was significantly higher in the LLN+/FR+ group compared with the LLN+/FR+ group (14.2% versus 6.9%, p<0.001) but the LLN+/FR+ group also had a significantly lower prevalence of depression (Table 2; Figure 2). The prevalence of asthma was significantly higher in the LLN+/FR+ group compared with the LLN-/FR− group (30.9% versus 18.4%, p<0.001). While this was also observed when comparing the LLN+/FR+ with the LLN-/FR+ group, this difference did not reach statistical significance. After adjusting for age and sex, the LLN+/FR+ group had a significantly lower probability of having heart disease compared with the LLN-/FR− group (odds ratio 0.57, 95% CI: 0.40–0.81) but no significant difference was found for the LLN-/FR+ group (Table 3). The same associations
COPD diagnosed by the fixed ratio and lower limit of normal

Discussion
Main findings

Within a primary care population of previously undiagnosed adults with chronic respiratory symptoms, using the FR to define airflow obstruction resulted in a higher proportion being classified as having COPD, compared with using the LLN criterion (32.6% versus 20.2%, respectively). Those diagnosed with COPD by the FR but not by LLN were older, and had better lung function, lower symptom burden, a higher prevalence of self-reported cardiovascular disease, and a lower prevalence of depression, compared with those classified as having COPD by both criteria. Those diagnosed

were found after adjusting for smoking status, self-reported diabetes mellitus, and hypertension.

Table 2
Self-reported symptoms, comorbidities and quality of life, stratified by diagnostic criteria

| Symptoms          | LLN−/FR+ | p-value | LLN+/FR+ | p-value | LLN+/FR− | N (%) |
|-------------------|----------|---------|----------|---------|----------|-------|
| Symptoms          | 527      |         | 324      |         | 1,753    |       |
| Symptoms          | 36 (6.9) | 0.109   | 46 (14.2)| 0.001   | 159 (9.1)|       |
| Symptoms          | 10 (1.9) | 0.086   | 13 (4.0) | 0.068   | 59 (3.4)|       |
| Symptoms          | 205 (39.2)| 0.697 | 161 (49.7)| 0.003 | 699 (40.1)|       |
| Symptoms          | 59 (11.3)| 0.022   | 58 (17.9)| 0.007   | 266 (15.3)|       |
| Symptoms          | 19 (3.6) | 0.129   | 20 (6.2) | 0.088   | 42 (2.4)|       |
| Symptoms          | 114 (21.8)| 0.776 | 36 (11.1)| 0.001   | 390 (22.4)|       |
| Symptoms          | 163 (30.9)| 0.001* | 74 (22.8)| 0.009   | 322 (18.4)|       |
| Symptoms          | 36 (6.9) | 0.109   | 46 (14.2)| 0.001   | 159 (9.1)|       |
| Symptoms          | 10 (1.9) | 0.086   | 13 (4.0) | 0.068   | 59 (3.4)|       |
| Symptoms          | 205 (39.2)| 0.697 | 161 (49.7)| 0.003 | 699 (40.1)|       |
| Symptoms          | 59 (11.3)| 0.022   | 58 (17.9)| 0.007   | 266 (15.3)|       |
| Symptoms          | 19 (3.6) | 0.129   | 20 (6.2) | 0.088   | 42 (2.4)|       |
| Symptoms          | 114 (21.8)| 0.776 | 36 (11.1)| 0.001   | 390 (22.4)|       |
| Symptoms          | 163 (30.9)| 0.001* | 74 (22.8)| 0.009   | 322 (18.4)|       |
| Symptoms          | 36 (6.9) | 0.109   | 46 (14.2)| 0.001   | 159 (9.1)|       |
| Symptoms          | 10 (1.9) | 0.086   | 13 (4.0) | 0.068   | 59 (3.4)|       |
| Symptoms          | 205 (39.2)| 0.697 | 161 (49.7)| 0.003 | 699 (40.1)|       |
| Symptoms          | 59 (11.3)| 0.022   | 58 (17.9)| 0.007   | 266 (15.3)|       |
| Symptoms          | 19 (3.6) | 0.129   | 20 (6.2) | 0.088   | 42 (2.4)|       |
| Symptoms          | 114 (21.8)| 0.776 | 36 (11.1)| 0.001   | 390 (22.4)|       |
| Symptoms          | 163 (30.9)| 0.001* | 74 (22.8)| 0.009   | 322 (18.4)|       |
| Symptoms          | 36 (6.9) | 0.109   | 46 (14.2)| 0.001   | 159 (9.1)|       |
| Symptoms          | 10 (1.9) | 0.086   | 13 (4.0) | 0.068   | 59 (3.4)|       |
| Symptoms          | 205 (39.2)| 0.697 | 161 (49.7)| 0.003 | 699 (40.1)|       |
| Symptoms          | 59 (11.3)| 0.022   | 58 (17.9)| 0.007   | 266 (15.3)|       |
| Symptoms          | 19 (3.6) | 0.129   | 20 (6.2) | 0.088   | 42 (2.4)|       |
| Symptoms          | 114 (21.8)| 0.776 | 36 (11.1)| 0.001   | 390 (22.4)|       |
| Symptoms          | 163 (30.9)| 0.001* | 74 (22.8)| 0.009   | 322 (18.4)|       |
| Symptoms          | 36 (6.9) | 0.109   | 46 (14.2)| 0.001   | 159 (9.1)|       |
| Symptoms          | 10 (1.9) | 0.086   | 13 (4.0) | 0.068   | 59 (3.4)|       |
| Symptoms          | 205 (39.2)| 0.697 | 161 (49.7)| 0.003 | 699 (40.1)|       |
| Symptoms          | 59 (11.3)| 0.022   | 58 (17.9)| 0.007   | 266 (15.3)|       |
| Symptoms          | 19 (3.6) | 0.129   | 20 (6.2) | 0.088   | 42 (2.4)|       |
| Symptoms          | 114 (21.8)| 0.776 | 36 (11.1)| 0.001   | 390 (22.4)|       |
| Symptoms          | 163 (30.9)| 0.001* | 74 (22.8)| 0.009   | 322 (18.4)|       |
| Symptoms          | 36 (6.9) | 0.109   | 46 (14.2)| 0.001   | 159 (9.1)|       |
| Symptoms          | 10 (1.9) | 0.086   | 13 (4.0) | 0.068   | 59 (3.4)|       |
| Symptoms          | 205 (39.2)| 0.697 | 161 (49.7)| 0.003 | 699 (40.1)|       |
| Symptoms          | 59 (11.3)| 0.022   | 58 (17.9)| 0.007   | 266 (15.3)|       |
| Symptoms          | 19 (3.6) | 0.129   | 20 (6.2) | 0.088   | 42 (2.4)|       |
| Symptoms          | 114 (21.8)| 0.776 | 36 (11.1)| 0.001   | 390 (22.4)|       |
| Symptoms          | 163 (30.9)| 0.001* | 74 (22.8)| 0.009   | 322 (18.4)|       |

Notes: *Unless otherwise specified. Results for LLN−/FR+ were compared with LLN+/FR+ ($$) and results for LLN+/FR+ were compared with LLN+/FR− ($$) using Pearson chi-square tests. *p-values ≤0.001 are statistically significant in accordance with Bonferroni correction for multiple comparisons.

Abbreviations: CAT, COPD Assessment Test; Chr, chronic; EQ-5D, EuroQol-5D (measure of quality of life); FR, fixed ratio; IQR, interquartile range; LLN, lower limit of normal; mMRC, modified Medical Research Council score.
with COPD by LLN were also significantly more likely to have a past history of asthma than those without airflow obstruction. In addition, using the LLN classified a smaller number of younger, very symptomatic females as having COPD that the FR excluded. Finally, symptomatic individuals with preserved lung function appeared to have a higher probability of having heart disease and a lower FVC than those with airflow limitation by LLN.

### Relationship to other studies

The potential for over-diagnosis of COPD using the FR has been previously demonstrated. A population prevalence study of COPD in England and Wales for ages 40–95 years found FR-defined airflow obstruction in 22% of subjects but in only 13% when using the LLN criterion.16 Our findings also agreed with an analysis of the CanCOLD study, a large prospective population-based cohort study of COPD in Canada.6 This concluded that use of the FR for diagnosing airflow obstruction could lead to the misdiagnosis of older males with a history of cardiovascular disease. The authors proposed using an FEV₁/ FVC < 0.7 as an additional criterion for restricting the diagnosis to patients with a clinically more significant degree of airflow obstruction. Indeed, this approach was previously recommended by NICE.3 However, this approach still does not adequately account for variation in lung function by age, sex, and height, and therefore, can still lead to misclassification.17 Using FEV₁ < LLN as an alternative criterion would avoid this bias.

The Austria Burden of Obstructive Lung Disease study similarly evaluated whether the diagnostic criterion for airflow obstruction was associated with the prevalence of heart disease.18 Among 1,258 screened adults aged >40 years (with and without symptoms), 27% of LLN+/FR− cases had self-reported heart disease compared to 15% of LLN+ cases.

It has been suggested that the LLN−/FR+ cases have COPD with heart disease as a comorbidity, which may account for their poorer prognosis in terms of higher risk of hospitalization and premature mortality.19 However, the observation that these individuals are older with a higher comorbidity burden, and yet have better lung function, suggests that heart disease may be their primary diagnosis. COPD is characterized by gradual and inexorable decline in lung function with increasing dyspnea and those with relatively good lung function would not be expected to have a high rate of early mortality from COPD.

It is well recognized that the FR criterion will not only over-diagnose airflow obstruction in the older population but also miss the diagnosis in younger females.5,6,21,22 In the current study, the 3 highly symptomatic females who were misclassified as having no airflow obstruction using the FR potentially have a lot to gain from clinical intervention.

A recent study of patients with COPD using a FR definition of airflow obstruction23 found marked differences in how subjects were classified by the 2011 GOLD symptom-related classification (A, B, C, and D)4 depending on whether the modified MRC (mMRC) or CAT scores were used to assess subjects. Use of the CAT score tended to reduce the prevalence of cardiac comorbidities in the 2 more severe groupings. The mMRC rating of dyspnea is not specific to respiratory disease whereas the CAT score measures disease-specific quality of life and includes 7 other domains, some being more specific to COPD. This lends weight to the possibility that a combination of mMRC dyspnea and FEV₁/FVC < 0.7 may over-represent primary cardiac disease rather than COPD.

Related to this, our study found that the prevalence of dyspnea was similar between individuals diagnosed with COPD by either diagnostic criterion whereas cough and sputum were less prevalent in the LLN−/FR+ group.

Guder et al prospectively studied 405 individuals aged >65 years with a GP diagnosis of COPD.24 They examined FR and LLN criteria for airflow obstruction and compared this with a COPD diagnosis by an expert panel that had access to clinical information, radiology, and lung

### Table 3 Logistic regression model evaluating the association between risk of heart disease and presence of airflow limitation by different criteria

|                      | Model 1 (n=2,589) | Model 2 (n=2,561) | Model 3 (n=2,559) |
|----------------------|-------------------|-------------------|-------------------|
| **Sex**              |                   |                   |                   |
| Female               | 1.00              | 1.00              | 1.00              |
| Male                 | 1.98 (1.51–2.59)  | 2.03 (1.54–2.67)  | 1.92 (1.46–2.54)  |
| Age                  | 1.08 (1.06–1.10)  | 1.07 (1.06–1.09)  | 1.07 (1.05–1.09)  |
| **Diagnostic group** |                   |                   |                   |
| LLN−/FR−             | 1.00              | 1.00              | 1.00              |
| LLN−/FR+             | 0.85 (0.60–1.21)  | 0.87 (0.61–1.23)  | 0.90 (0.63–1.29)  |
| LLN+/FR+             | 0.57 (0.40–0.81)  | 0.59 (0.41–0.85)  | 0.62 (0.43–0.90)  |
| **Smoking status**   |                   |                   |                   |
| Never                | 1.00              | 1.00              | 1.00              |
| Former               | 0.99 (0.72–1.38)  | 0.98 (0.71–1.37)  |                   |
| Current              | 0.87 (0.57–1.32)  | 0.89 (0.58–1.36)  |                   |
| **Co-morbidities**   |                   |                   |                   |
| Diabetes             |                    | 1.71 (1.26–2.32)  |                   |
| Hypertension         | 1.73 (1.32–2.27)  |                   |                   |

**Notes:** Heart disease was defined by the presence of self-reported heart disease (n=241) or heart failure (n=82) or both (n=35). The LLN−/FR− group was the reference group with Model 1 adjusted for sex and age, Model 2 also adjusted for smoking status, and Model 3 also adjusted for diabetes mellitus and hypertension (n=2,559 with complete data).

**Abbreviations:** FR, fixed ratio (FEV₁/FVC < 0.7); LLN, lower limit of normal (FEV₁/FVC < 5th percentile); OR, odds ratio; FEV₁, forced expiratory volume in 1 s; FVC, forced vital capacity.
function. Both criteria misclassified patients when using the expert panel diagnosis as the reference standard. The FR criterion was associated with more false positive diagnoses and the LLN criterion with more false negatives. Expert panel diagnosis was a better predictor of exacerbations, hospitalizations, and mortality, than either the FR or LLN criteria, highlighting the importance of a holistic assessment in addition to lung function measurement for making an accurate diagnosis and predicting prognosis.

Strengths and limitations

Our study had a large sample of symptomatic subjects recruited from primary care who are likely to be representative of those who would be targeted for COPD case finding. The study employed post-bronchodilator spirometry with rigorous quality assurance and collected a broad range of data on symptoms, comorbidities, and health-related quality of life, and accounted for multiple statistical comparisons.

Comorbidities were self-reported and not based on health records or objective measures. We also did not account for potential undiagnosed comorbidities. Current and former smokers appeared to have a lower risk of self-reported cardiovascular disease than never smokers, although this association was not statistically significant. The reason for this is unclear but may be because cardiovascular disease was self-reported, which would not account for undiagnosed cardiovascular disease.

There was also a significant amount of missing data for the CAT (12.8% missing) and MRC dyspnea (4.1% missing) scores, and no data on objective measures of exercise tolerance, lung imaging, gas transfer, or cardiac function were collected. Finally, only 35% of all eligible participants responded to the respiratory questionnaire and the findings are therefore potentially prone to responder bias.

Implications for practice, policy, and research

Use of the FR for defining airflow obstruction may lead to the inclusion of a significant number of older patients with a history of cardiovascular disease as having COPD. This could lead to symptoms related to cardiovascular disease being falsely attributed to airflow obstruction, resulting in an inappropriate management strategy. It is particularly important that symptomatic patients with an FEV/FVC above the LLN (irrespective of whether the FEV/FVC is <0.7) are diagnostically assessed for cardiovascular causes of their symptoms and exacerbations. Cardiovascular morbidity and mortality are higher in people with COPD than they are in the general population and cardiovascular disease is a more common cause of death among these individuals than COPD itself. Furthermore, the early mortality in those with an FEV/FVC<0.7 and with mild reduction in FEV, has been found to be unexpectedly high due to cardiac disease.

It will be important to investigate whether cardiovascular disease is predominantly responsible for the symptom burden experienced by these patients. This could include more detailed investigations for cardiovascular disease, including echocardiography.

Further research is also needed to understand the clinical implications and long-term outcomes of pursuing standard treatment for COPD in the LLN/FR+ group. The burden of respiratory symptoms was generally lower in this group compared with those with airflow obstruction by LLN. This may potentially explain the difference in prevalence of depression, since these physical symptoms may contribute to poor mental health. However, this requires further investigation. Further investigation is also needed to understand the significantly high burden of self-reported asthma seen in those with airflow limitation by LLN.

The growing body of evidence that using the FR has the potential to over-diagnose COPD in older people with cardiovascular disease and underdiagnose younger females should be more fully acknowledged in clinical guidelines, with a recommendation to use the LLN criterion to help differentiate patients with COPD from those with a potential cardiovascular cause for breathlessness. This will be particularly important in the context of systematic case finding, where there is a significant risk of misdiagnosing large numbers of people.

Conclusion

Use of the FR for defining airflow obstruction may lead to the inclusion of a significant number of older people with breathlessness as having COPD, who may, in fact, have age-related changes in lung function in the presence of cardiovascular disease as the cause for their symptoms. Further research is needed to assess the long-term outcomes and clinical implications of using the FR versus the LLN for diagnosing COPD and characterize cardiovascular health in symptomatic subjects with lung function that is within the normal population reference range.

Acknowledgments

We would like to thank Nicola Adderley, Joanne O’Beirne-Elliman, and the Birmingham Lung Improvement Studies (BLISS) Team for the successful execution of the TargetCOPD trial. Most of all we would like to thank all the patients, including those in the BLISS patient advisory group,
who participated in the TargetCOPD trial. This paper summarises independent research funded by the National Institute for Health Research (NIHR) under its Programme Grants for Applied Research Programme (Grant Reference Number RP-PG-0109-10061). The views expressed are those of the authors and not necessarily those of the NHS, the NIHR or the Department of Health. TargetCOPD is part of the Birmingham Lung Improvement Studies: BLISS.

Disclosure
The authors report no conflicts of interest in this work.

References
1. GBD 2013 Mortality and Causes of Death Collaborators. Global, regional, and national age-sex specific all-cause and cause-specific mortality for 240 causes of death, 1990–2013: a systematic analysis for the Global Burden of Disease Study 2015. Lancet. 2015;385(9963):117–171.
2. Vogelmeier CF, Criner GJ, Martinez FJ, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive lung disease 2017 report. GOLD executive summary. Am J Respir Crit Care Med. 2017;195(5):557–582.
3. National Institute for Health and Clinical Excellence: Guidance. Chronic Obstructive Pulmonary Disease: Management of Chronic Obstructive Pulmonary Disease in Adults in Primary and Secondary Care. London: National Institute for Health and Clinical Excellence; 2010.
4. Swanney MP, Ruppel G, Enright PL, et al. Using the lower limit of normal for the FEV1/FVC ratio reduces the misclassification of airway obstruction. Thorax. 2008;63(12):1046–1051.
5. Miller MR, Levy ML. Chronic obstructive pulmonary disease: missed diagnosis versus misdiagnosis. BMJ. 2015;351:h3021.
6. van Dijk W, Tan W, Li P, et al; CanCOLD Study Group. Clinical relevance of fixed ratio vs lower limit of normal of FEV1/FVC in COPD: patient-reported outcomes from the CanCOLD cohort. Ann Fam Med. 2015;13(1):41–48.
7. Singh S, Loke YK, Furberg CD. Inhaled anticholinergics and risk of major adverse cardiovascular events in patients with chronic obstructive pulmonary disease: a systematic review and meta-analysis. JAMA. 2008;300(12):1439–1450.
8. Gershon A, Croxford R, Calzavara A, et al. Cardiovascular safety of inhaled long-acting bronchodilators in individuals with chronic obstructive pulmonary disease. JAMA Intern Med. 2013;173(13):1175–1185.
9. Lung function testing: selection of reference values and interpretative strategies. American Thoracic Society. Am Rev Respir Dis. 1991;144(5):1202–1218.
10. Quanjer PH, Stanojevic S, Cole TJ, et al; ERSGlobal Lung Function Initiative. Multi-ethnic reference values for spirometry for the 3–95-year age range: the global lung function 2012 equations. Eur Respir J. 2012;40(6):1324–1343.
11. Jordan RE, Lam KB, Cheng KK, et al. Case finding for chronic obstructive pulmonary disease: a model for optimizing a targeted approach. Thorax. 2010;65(6):492–498.
12. Jordan RE, Adab P, Jowett S, et al. TargetCOPD: a pragmatic randomised controlled trial of targeted case finding for COPD versus routine practice in primary care: protocol. BMC Pulm Med. 2014;14(1):157.
13. Jordan RE, Adab P, Sitch A, et al. Targeted case finding for chronic obstructive pulmonary disease versus routine practice in primary care (TargetCOPD): a cluster-randomised controlled trial. Lancet Respir Med. 2016;4(9):720–730.
14. Bland JM, Altman DG. Multiple significance tests: the Bonferroni method. BMJ. 1995;310(6973):170.
15. Kon SS, Canavan JL, Jones SE, et al. Minimum clinically important difference for the COPD Assessment Test: a prospective analysis. Lancet Respir Med. 2014;2(3):195–203.
16. Scholes S, Moody A, Mindell JS. Estimating population prevalence of potential airflow obstruction using different spirometric criteria: a pooled cross-sectional analysis of persons aged 40–95 years in England and Wales. BMJ Open. 2014;4(7):e005685.
17. Miller MR, Quanjer PH, Swanney MP, Ruppel G, Enright PL. Interpreting lung function data using 80% predicted and fixed thresholds misclassifies more than 20% of patients. Chest. 2011;139(1):52–59.
18. Lamprecht B, Schirnhofer L, Kaiser B, Buist SA, Mannino DM, Studnicka M. Subjects with discordant airways obstruction: lost between spirometric definitions of COPD. Pal M Med. 2011;2011:780215.
19. Mannino DM, Thorn D, Swensen A, Holguín F. Prevalence and outcomes of diabetes, hypertension and cardiovascular disease in COPD. Eur Respir J. 2008;32(4):962–969.
20. Lange P, Marott JL, Vestbo J, et al. Prediction of the clinical course of chronic obstructive pulmonary disease, using the new GOLD classification: a study of the general population. Am J Respir Crit Care Med. 2012;186(10):975–981.
21. Quanjer PH, Brazzale DJ, Borows PW, Petro J. Implications of adopting the Global lungs initiative 2012 all-age reference equations for spirometry. Eur Respir J. 2013;42(4):1046–1054.
22. Bhatt SP, Washko GR, Dransfield MT, Sieren JC, Newell JD Jr, Hoffman EA. Comparison of spirometric thresholds in diagnosing smoking-related airflow obstruction: authors’ response. Thorax. 2014;69(12):1147–1148.
23. Han J, Dai L, Zhong N, Young D. Breathlessness or health status in chronic obstructive pulmonary disease: the impact of different definitions. COPD. 2015;12(2):115–125.
24. Global Strategy for the Diagnosis, Management and Prevention of COPD. Global Initiative for Chronic Obstructive Lung Disease (GOLD); 2011.
25. Güder G, Brenner S, Angermann CE, et al. “GOLD or lower limit of normal definition? A comparison with expert-based diagnosis of chronic obstructive pulmonary disease in a prospective cohort-study”. Respir Res. 2012;13(1):13.
26. Huiart L, Ernst P, Sussa S. Cardiovascular morbidity and mortality in COPD. Chest. 2005;128(4):2640–2646.